News

11/12/2017

FDA Approves Once-Weekly Semaglutide for Type 2 Diabetes

The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic […]